Spyre Therapeutics | 8-K:重大事件
Spyre Therapeutics | 424B5:募资说明书
Spyre Therapeutics | 424B5:募资说明书
Spyre Therapeutics | 10-Q/A:季度报表(修正版)
Spyre Therapeutics | 10-Q/A:季度报表(修正版)
Spyre Therapeutics | 10-Q/A:季度报表(修正版)
Spyre Therapeutics | 10-K/A:年度报表(修正版)
Spyre Therapeutics | 8-K:重大事件
Spyre Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Venrock Healthcare Capital Partners III, L.P.(5.3%),VHCP Co-Investment Holdings III, LLC(5.3%)等
Spyre Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Perceptive Advisors LLC(5.7%),Joseph Edelman(5.7%)等
Spyre Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Commodore Capital LP(3.9%),Commodore Capital Master LP(3.9%)
Spyre Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Deep Track Capital, LP(1.97%),Deep Track Biotechnology Master Fund, Ltd.(1.97%)等
Spyre Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Avoro Capital Advisors LLC(1.7%),Behzad Aghazadeh(1.7%)
Spyre Therapeutics | 8-K:重大事件
Spyre Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-FMR LLC(14.999%),Abigail P. Johnson(14.999%)
Spyre Therapeutics | 4:持股变动声明-董事 Albers Jeffrey W.
Spyre Therapeutics | SC 13G:超过5%持股股东披露文件-BlackRock, Inc.(5.2%)
Spyre Therapeutics | S-8:员工福利计划证券登记
Spyre Therapeutics | 8-K:Spyre Therapeutics公布2024年第三季度财务业绩并提供公司最新情况
Spyre Therapeutics | 10-Q:2024财年三季报